High-content analysis (HCA) has rapidly established itself as a core technology in drug discovery for secondary cell-based screening. When combined with our knowledge of genetics, HCA can provide a powerful tool for target validation, but excitingly, HCA may also enable the increased use of cellular assays in high-throughput screening for novel drug leads.